PPP1R15A and hypertensive disorder: In contrast, guanabenz, an FDA-approved α2-adrenergic receptor agonist formerly used in clinical practice for the treatment of hypertension [45], has been found to efficiently inhibit GADD34-PP1 complex independently from α2-adrenergic agonism [46].